Conference abstract · 20 Mar 2019
Conference abstractPublished 23 Oct 2017
Non-small cell lung (NSCL) cancer search for biomarkers from body fluids to microarrays
Foundation T. & L. de Beaumont Bonelli for cancer research, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Lung and bronchus cancers are still one of the most common cancers worldwide, and the estimated numbers of new cases and deaths are more than 2.2 and 1.5 million respectively in the United States in 2013. Despite multi-model treatment strategies, including surgery, radiotherapy, chemotherapy and targeted therapy are used, the death rate of lung cancer is still the first leading cause of cancer-related death both in the World and in the America. The 5-year survival rate of lung cancer, predominantly NSCLC, remains as low as 15%. Therefore, improvements in diagnostics (marker associated with different degrees of malignancy and the consequent clinical behaviour of lung tumors) and treatments are urgently needed. Serological markers such as CEA, NSE (neuron-specific enolase) and Cyfra 21-1 are included in the diagnosis and management of lung cancer, but their diagnostic and prognostic value is still being debated and currently the usefulness of tumor associated antigenic biomarkers in the care of patients with lung cancer is limited. Panel of markers has gained widespread acceptance as a diagnostic test, as a prognostic indicator, or as a monitor of the treatment response. In fact, no useful marker for the screening of asymptomatic patients has been identified to date. Ideally, a biomarker should have one strategy of potentially increase both sensitivity and specificity parameters combining several biomarkers into a prognostic panel. Identification of lung cancer-specific biomarkers, together with other noninvasive methods, may allow for much needed further refinement of lung cancer screening to reduce mortality.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Sep 2017
15-lipoxygenases and their metabolites as biomarkers for the early detection of smoking-induced non-small cell lung cancer
Conference abstract · 27 Sep 2017
15-lipoxygenases and their metabolites as biomarkers for the early detection of smoking-induced non-small cell lung cancer
Conference abstract · 2016
Biomarkers in the accurate classification of non-small cell lung carcinomas (NSCLC) for targeted therapies: An evidence-based practice
Research article · 30 Jan 2017
Immunogenic chemotherapy sensitizes non-small cell lung cancer to immune checkpoint blockade therapy in preclinical models
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOncology & Cancer
- SubjectPathology & Lab Medicine
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Giulio Tarro”
